Bakuchiol Contributes to the Hepatotoxicity of Psoralea corylifolia in Rats

Zhi‐Jian Li,Abudumijiti Abulizi,Guo‐Lin Zhao,Tao Wang,Fan Zhou,Zhen‐Zhou Jiang,Silafu Aibai,Lu‐Yong Zhang,Zhi-Jian Li,Guo-Lin Zhao,Zhen-Zhou Jiang,Lu-Yong Zhang
DOI: https://doi.org/10.1002/ptr.5851
IF: 6.388
2017-06-22
Phytotherapy Research
Abstract:Psoralea corylifolia L. (Fructus Psoraleae) is widely used in Asia, but there are concerns about hepatotoxicity caused by constituents such as psoralens and bakukiol. Bakuchiol (BAK) has antiinflammatory, antipyretic, antibacterial antiviral, anticancer, and estrogenic activity but appears to be hepatotoxic in in vitro tests. This study investigated the hepatotoxicity in vivo in rats. Using intragastrically administered bakuchiol at doses of 52.5 and 262.5 mg/kg for 6 weeks. Bodyweight, relative liver weight, biochemical indicators, histopathology, mRNA expression of CYP7A1, HMG-CoA reductase, BSEP, PPARα, SREBP-2, and MRP3 were measured. Many abnormalities were observed in the bakuchiol-treated groups including suppression of weight gain and food intake, change of some parameters in serum biochemistry, and increased weight of liver. The mRNA expression of CYP7A1, HMG-CoA reductase, PPARα, and SREBP-2 decreased in bakuchiol-treated group, the expression of BSEP increased in bakuchiol-treated low dosage, and the expression of BSEP decreased in bakuchiol-treated high dosage. In conclusion, we provide evidence for the first time that bakuchiol can induce cholestatic hepatotoxicity, suggesting potential hepatotoxicity. The mechanism may be related to effects on liver lipid metabolism, but further investigation is necessary. Copyright © 2017 John Wiley & Sons, Ltd.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?